

Application No.: 09/155,252
Applicant: Evans, et. al.
Filed: September 21, 1998
2

PATENT
Attorney Docket No.: SALK1470-2
(088802-1852)

At page 1, line 1, please insert

--RELATED APPLICATIONS

E2
This application is a divisional of United States Serial No. 08/465,375, filed June 5, 1995, now issued as U.S. Patent No. 6,022,897, which is a continuation-in-part of United States Serial No. 08/428,559, filed April 25, 1995, now abandoned.--

IN THE CLAIMS

Please replace the prior version of claims 18 and 19 with the re-written claims presented below, which reflect amendments to these claims. In addition, please add new claims 27 and 28 and cancel claim 21 without prejudice. Enclosed herewith is an Appendix explicitly illustrating the amendments to these claims. Unamended claims are also presented in the Appendix marked as reiterated.

E3
18. A method according to claim 17 wherein said response element has at least one copy of the minimal sequence:

AGGACA A AGGTCA (SEQ. ID NO. 5),

12 wherein said minimal sequence is optionally flanked by additional residues.

19. A method according to claim 17 wherein said response element has at least one copy of the sequence:

GGACC AGGACA A AGGTCA CGTTC (SEQ. ID NO. 6).

E4 July 17
27. A method according to Claim 16 wherein said contacting is carried out in the further presence of at least one PPAR- γ agonist.

28. A method according to Claim 16 wherein said contacting is carried out in the further presence of at least one PPAR- γ antagonist.